TOTAL VOLUME:
$147.3b
24H VOL:
$172,964,198
24H TRANSACTIONS:
2,798,566,680
OPEN INTEREST:
$1,800,387,182
518,213
Markets across
38,398
events
MATCHED EVENTS:
2,848
PLATFORM COVERAGE:
5
Polymarket:
38%
VS.
Kalshi:
62%
New COVID variant of concern before 2027?
- Polymarket
New COVID variant of concern before 2027? - Polymarket
1W
News
Positive
Negative
Neutral
Hover marker for details
Vol.
·
Resolves Dec 31, 2026
$
This market will resolve to "Yes" if the CDC identifies a new COVID variant of concern between December 1, 2025, and December 31, 2026, 11:59PM ET. Otherwise this market will resolve to "No". The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682. The resolution source for this market will be official information from the CDC.
This market will resolve to "Yes" if the CDC identifies a new COVID variant of concern between December 1, 2025, and December 31, 2026, 11:59PM ET. Otherwise this market will resolve to "No". The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682. The resolution source for this market will be official information from the CDC.
On Polymarket, this market is priced using a continuous double auction. Traders buy and sell shares representing their belief about whether a new COVID variant of concern will emerge before Jan 1, 2027. The price of these shares fluctuates based on supply and demand, directly reflecting the collective probability assigned to the event. On Polymarket, prices reflect that venue's order book, liquidity, and how traders price the outcome right now. The closer the resolution date, the more sensitive the price becomes to new information and shifts in sentiment. Currently, the market is indicating a significant level of uncertainty surrounding the future evolution of the virus.
This market resolves around Jan 1, 2027, with the outcome confirmed once the event is verifiable from credible public reporting. Specifically, the resolution will depend on whether the World Health Organization (WHO) or a comparable national public health agency officially designates a new COVID variant as a ‘variant of concern’ before that date. The designation must be publicly available and widely reported to be considered for resolution of this market. The outcome will be a simple binary determination: yes, a variant of concern was identified, or no, it was not.
Several factors could significantly influence this market. The emergence of a new variant with concerning characteristics – such as increased transmissibility, immune evasion, or severity – would likely drive up the price. Conversely, positive news regarding vaccine efficacy against existing and emerging variants, or a sustained decline in global case numbers, could lower the price. Official statements from public health organizations like the WHO, as well as scientific publications detailing the properties of new variants, are also key catalysts that could move this market before Jan 1, 2027.